Xin An Prison
Welcome,         Profile    Billing    Logout  
 17 Trials 
11 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chen, Jing X
NCT06406205: A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis

Recruiting
3
270
RoW
Voclosporin（QL1074）, Placebo
Qilu Pharmaceutical Co., Ltd.
Lupus Nephritis
06/27
06/28
TAK-620-2004, NCT05319353 / 2021-004279-15: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

Active, not recruiting
3
80
Europe, Japan, US, RoW
Maribavir, TAK-620
Takeda, Takeda Development Center Americas, Inc.
Cytomegalovirus (CMV)
01/27
01/27
NCT05114603: A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation

Recruiting
2
30
RoW
HLX208
Shanghai Henlius Biotech
Advanced Melanoma
08/23
08/24
NCT05046314: A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma

Recruiting
2
30
RoW
TK216+Vincristin
Shanghai Pharmaceuticals Holding Co., Ltd
Sarcoma, Ewing
09/25
12/25
ARTEMIS-002, NCT05830123: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

Recruiting
2
170
RoW
HS-20093
Hansoh BioMedical R&D Company
Osteosarcoma, Sarcoma
12/25
12/27
NCT04390737: Evaluate the Safety and Clinical Activity of HH2853

Recruiting
1/2
254
US, RoW
HH2853 Tablets
Haihe Biopharma Co., Ltd.
FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
12/25
12/25
AUGMENT-101, NCT04065399 / 2020-004104-34: A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Jan 2024 - Dec 2024: Market entry for acute leukemias
Hourglass Feb 2024 - Mar 2024 : Q1'24 - PDUFA date from FDA for R/R KMT2Ar acute leukemia
Dec 2022 - Dec 2023: Submission in US for relapsed/refractory acute leukemia
Jul 2023 - Sep 2023: Data from AUGMENT-101 trial for r/r AML
Checkmark Updated data from P1 portion of P1/2 AUGMENT-101 trial for AML
More
Recruiting
1/2
413
Europe, Canada, US, RoW
revumenib, SNDX-5613, cobicistat
Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
12/27
12/27
NCT05944224: A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

Recruiting
1/2
63
RoW
SPH4336, Cadonilimab
Shanghai Pharmaceuticals Holding Co., Ltd
Advanced Solid Tumors
05/25
12/25
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies

Recruiting
1
258
Europe, US, RoW
NB003 tablets
Ningbo Newbay Technology Development Co., Ltd
Advanced Solid Tumor
07/25
12/25
NCT04033627: TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia

Recruiting
N/A
30
RoW
In Vitro T cells depletion using CliniMCAS system
Shanghai Children's Medical Center, Nanfang Hospital of Southern Medical University, Children's Hospital Of Soochow University, Chinese University of Hong Kong, Miltenyi Biomedicine GmbH
Relapsed Pediatric ALL, Acute Graft-Versus-Host Disease (Gvhd) Grade IV (Diagnosis), Relapsed Pediatric AML
07/22
05/24
NCT05918913: Expanded Access Program for Revumenib

Available
N/A
US
Revumenib, SNDX-5613
Syndax Pharmaceuticals
Relapsed/Refractory Acute Leukemia
 
 

Download Options